{{Rsnum
|rsid=34241435
|Gene=SCNN1B
|Chromosome=16
|position=23301864
|Orientation=plus
|GMAF=0.1088
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SCNN1B
}}{{PharmGKB
|RSID=rs34241435
|Name_s=
|Gene_s=SCNN1B
|Feature=
|Evidence=PubMed ID:18004211
|Annotation=A study in 207 Caucasian participants receiving farglitazar plus insulin or glyburide combination therapies this polymorphism in the SCNN1B gene was significantly associated with oedema. This variant in the promoter region of the gene was predicted to modify transcriptional interactions and in a transfected COS cell luciferase reporter gene assay exhibited higher promoter activity. The identified association has low penetrance in the fluid retention/oedema case population reflecting that SCNN1B variation may be only one of the covariates that contribute to the development of PPAR[gamma]-induced fluid retention.
|Drugs=glibenclamide; insulin-glargine
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA162355505
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs34241435
|overall_frequency_n=20
|overall_frequency_d=128
|overall_frequency=0.15625
|n_genomes=16
|n_genomes_annotated=0
|n_haplomes=18
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}